Bristol Myers (BMY) said studies demonstrated iza-bren achieved statistically significant in overall survival and progression-free survival in heavily pretreated, unresectable locally advanced or metastatic triple-negative breast cancer

Newsquawk StaffPublished On the live feed at 3 more headlines followed before this page went public
Newsquawk headlinesUTC

US BROKER MOVES: META upgraded at Arete; SHW downgraded at UBS

IBM (IBM) has announced plans to invest more than USD 10bln in quantum computing over the next five years

Bristol Myers (BMY) said studies demonstrated iza-bren achieved statistically significant in overall survival and progression-free survival in heavily pretreated, unresectable locally advanced or metastatic triple-negative breast cancer

AstraZeneca (AZN LN) announces results from the Phase III SERENA-6 trial showed camizestrant plus a cyclin-dependent kinase 4/6 inhibitor - palbociclib, ribociclib or abemaciclib - maintained its progression-free survival benefit

Ukraine and Moldova are expected to begin formal EU accession talks in June, Politico reports

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.

Related headlines

The whole workspace, free to try.

Try it free